"IgG-Fc Engineering for Therapeutic Use", InvivoGen Insight, 1 April 2006 (2006-04-01), pages 1-1, XP055115122, Retrieved from the Internet: URL:http://www.invivogen.com/docs/Insight2 00605.pdf [retrieved on 2014-04-24] (B1)

AKITO NATSUME ET AL: "Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 10, 15 May 2008 (2008-05-15), pages 3863-3872, XP007913550, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-6297 (B1)

CANFIELD S M ET AL: "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483-1491, XP001181027, ISSN: 0022-1007, DOI: 10.1084/JEM.173.6.1483 (B1)

CHAPPEL M S ET AL: "IDENTIFICATION OF THE FC-GAMMA RECEPTOR CLASS I BINDING SITE IN HUMAN IGG THROUGH THE USE OF RECOMBINANT IGG1-IGG2 HYBRID AND POINT-MUTATED ANTIBODIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 88, no. 20, 1 October 1991 (1991-10-01), pages 9036-9040, XP002392092, ISSN: 0027-8424, DOI: 10.1073/PNAS.88.20.9036 (B1)

GREENWOOD J ET AL: "STRUCTURAL MOTIFS INVOLVED IN HUMAN IGG ANTIBODY EFFECTOR FUNCTIONS", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 23, no. 5, 1 January 1993 (1993-01-01), pages 1098-1104, XP009029660, ISSN: 0014-2980, DOI: 10.1002/EJI.1830230518 (B1)

XU Y ET AL: "RESIDUE AT POSITION 331 IN THE IGG1 AND IGG4 CH2 DOMAINS CONTRIBUTES TO THEIR DIFFERENTIAL ABILITY TO BLIND AND ACTIVATE COMPLEMENT", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 269, no. 5, 4 February 1994 (1994-02-04), pages 3469-3474, XP002050452, ISSN: 0021-9258 (B1)

ROB C. AALBERSE ET AL: "IgG4 breaking the rules", IMMUNOLOGY, vol. 105, no. 1, 1 January 2002 (2002-01-01), pages 9-19, XP055115132, ISSN: 0019-2805, DOI: 10.1046/j.0019-2805.2001.01341.x (B1)

ROTHER R P ET AL: "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 12 December 2007 (2007-12-12), pages 1256-1264, XP002553743, ISSN: 1087-0156, DOI: 10.1038/NBT1344 [retrieved on 2007-11-07] (B1)

ROUX K H ET AL: "Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE and IgA2, to form small immune complexes: Arole for flexibility and geometry", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 161, 1 January 1998 (1998-01-01), pages 4083-4090, XP002970810, ISSN: 0022-1767 (B1)

SALFELD JOCHEN G: "Isotype selection in antibody engineering", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, UNITED STATES, vol. 25, no. 12, 1 December 2007 (2007-12-01), pages 1369-1372, XP002668461, ISSN: 1546-1696 (B1)

WO-A1-2013/012733 (B1)

INVIVOGEN: "IgG-Fc engineering for therapeutic use", INTERNET CITATION, 14 October 2007 (2007-10-14), pages 1-2, XP002616317, Retrieved from the Internet: URL:http://www.invivogen.com/ressource.php ?ID=22 [retrieved on 2011-01-12] (B1)